663P Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma failing first-line therapy: An open-label, single-arm, phase II study

X Ding,Y-F Ouyang,L You-Ping,C Lin,L Peng,X Zou,W Zhang,P.Y Huang,R You,Y Hua,X Yulong,M Chen,C-M Gu,Y-L Liu,C-Y Duan,Q Yang,Z Wang,S-Y Chen

doi:10.1016/j.annonc.2022.07.787

663P Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma failing first-line therapy: An open-label, single-arm, phase II study

X Ding, Y-F Ouyang + Show 16 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.787

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: Sun Yat-sen University Cancer Center, Sun Yat-sen University, Southern Medical University, Kunming Medical University, First Affiliated Hospital of Kunming Medical University

#Apatinib In Patients #Safety Of Camrelizumab + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Immune-checkpoint inhibitor (ICI) combined with antiangiogenic therapy have the potential for synergistic activity through modulation of the microenvironment. We report the activity and safety of camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who were refractory to at least one line of systemic therapy.

Full Text